Researchers at McMaster University have started a phase 2 clinical trial of an inhaled COVID-19 vaccine.
The AeroVax inhaled COVID-19 vaccine trial recently received an $8 million boost from the Canadian Institutes of Health Research (CIHR).
WATCH:
The road to hell is paved with good intentions…
AeroVax Inhaled COVID vaccine administration process
Administration of the innovative AeroVax Inhaled COVID Vaccine.
Source: AeroVax (YouTube) pic.twitter.com/gGknrJ6BUT
— Camus (@newstart_2024) May 2, 2025
Per AeroVax:
This new vaccine, named ChAd-triCoV/Mac, targets three different proteins in the SARS CoV-2 virus to improve the vaccine’s ability to protect against new strains (or variants) of the COVID virus.
The AeroVax Trial is a Phase 2 clinical trial funded by the Canadian Institutes of Health Research (CIHR), Canada’s federal funding agency for
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!